HF
RNAZ icon

HRT Financial’s TransCode Therapeutics RNAZ Stock Holding History

HRT Financial’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$5K – 2973
2023
Q4 		$5K Buy
+1
New +$11.2K ﹤0.01% 2131
2023
Q3 		– Hold
0
– – – 2146
2023
Q1 		– Hold
0
– -$17K – 3093
2022
Q4 		– Hold
0
– – – 2190

Other funds holding RNAZ

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FPFS
First Personal Financial Services Charlotte, North Carolina $473M AUM 28.33% 1-Year Est. Return

HRT Financial's RNAZ Position: Q1 2024 in Review

HRT Financial sold out of TransCode Therapeutics (RNAZ) in Q1 2024, closing a stake of 1 share — an estimated $5K sold.

HRT Financial first reported a position in RNAZ in Q4 2023 and held it in 1 quarter. The position peaked at $5K in Q4 2023. 4 funds tracked by Wall St. Rank hold RNAZ as of Q1 2024.

  • HRT Financial reported no remaining TransCode Therapeutics position as of Q1 2024 after selling out during the quarter.
  • HRT Financial sold 1 TransCode Therapeutics share in Q1 2024, an estimated $5K.
  • HRT Financial first reported a position in TransCode Therapeutics in Q4 2023 and held it in 1 quarter.
  • HRT Financial's TransCode Therapeutics position peaked at $5K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.